It’s been two days since Compass Pathways provided a first look at data from its Phase 3 program, by way of a limited readout from COMP005, a placebo-controlled study of its COMP360 psilocybin in treatment-resistant depression (TRD). (See Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle.) The stock market had a similarly dramatic reaction to that seen in 2021, when the company posted Phase…
